Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of YZJ-1139 in Hepatic Impairment
NCT06671509Phase 1Completed
- Sponsor
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fazamorexant in Insomnia (3 arms), sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity and 5 more. Started Mar 2024; status: completed.
02
Drugs
fazamorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06671509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671509.